Osanetant Sanofi-Synthélabo

Current Opinion in Investigational Drugs

Volumn 2, Issue 7, 2001, Pages 950-956

  Kamali, F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; 3 [1 [2 [4 BENZOYL 2 (3,4 DIFLUOROPHENYL) 2 MORPHOLINYL]ETHYL] 4 PHENYL 4 PIPERIDINYL] 1,1 DIMETHYLUREA; CAPSAICIN; HALOPERIDOL; NALOXONE; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR AGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROKININ A [4-10][10 NORLEUCINE]; NEUROKININ A [4-10][5 LYSINE 9 METHYLLEUCINE 10 NORLEUCINE]; NEUROKININ A [4-10][8 BETA ALANINE]; NEUROKININ A[4-10][7 TRYPTOPHAN 8 BETA ALANINE]; NEUROKININ B [7 METHYLPHENYLALANINE]; NOLPITANTIUM; OSANETANT; PLACEBO; R 820; SAREDUTANT; SENKTIDE; SUBSTANCE P [5-11][5 PYROGLUTAMIC ACID 8 (4 METHYLPHENYLALANINE) 9 SARCOSINE]; SUBSTANCE P [9 SARCOSINE 11 METHIONINE DIOXIDE]; UNCLASSIFIED DRUG; VOFOPITANT;

ANXIETY NEUROSIS; BINDING AFFINITY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG MARKETING; DRUG SYNTHESIS; HUMAN; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CARDIOVASCULAR SYSTEM; DOPAMINE; HUMANS; PIPERIDINES; RECEPTORS, NEUROKININ-3; SCHIZOPHRENIA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TACHYKININS;

EID: 0034921496     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Differences in neurokinin receptor pharmacology between rat and guinea-pig superior cervical ganglia
2. The nonpeptide NK-2 antagonist SR 48968 is also a NK-3 antagonist in the guinea but not in the rat
3. Different behavioral profiles of the non-peptide substance P (NK1) antagonists CP-96,345 and RP 67580 in Swiss albino mice in the black-and-white box
4. Pharmacology of CP-99994: A non-peptide antagonist of the tachykinin neurokinin-1 receptor
5. Pipeline news: Focus on Sanofi
6. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor
7. Antagonism by SR-142801, a non-peptide NK(3) receptor antagonist, of senktide-evoked increase in firing rate in guinea-pig locus coeruleus slices
8. The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists
9. Activity of SR 142801 at peripheral tachykinin receptors
10. Functional characterization of the non-peptide NK3 receptor antagonist, SR142801 on the human NK3 receptor expressed in CHO cells
11. Nitric oxide is a mediator of tachykinin NK3 receptor-induced relaxation in rat mesenteric artery
12. Effect of SR-142801 on nitric oxide-dependent and independent responses to tachykinin NK3 receptor antagonists in isolated guinea-pig colon
13. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor
14. Neurokinin receptor antagonists
15. Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box
16. 2-Phenyl-4-quinolonecarboxamides: A novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor
17. Involvement of tachykinin receptors in oedema formation and plasma extravasation induced by substance P, neurokinin A, and neurokinin B in mouse ear
18. Effect of the tachykinin receptor antagonists, SR 140333, FK 888, and SR 142801, on capsaicin-induced mouse ear edema
19. Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig
20. A reliable and efficient synthesis of SR 142801
21. Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: Characterization of novel tachykinin receptor antagonists
22. Characterization of NK3 receptors in rabbit isolated iris sphincter muscle
23. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice
24. A practical and scalable synthesis of SR-142801, a tachykinin NK3 antagonist
25. Potency and selectivity of the tachykinin NK3 receptor antagonist SR 142801
26. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor
27. Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: An in vitro electrophysiological study
28. Recent advances in neurokinin receptor antagonists
29. Sanofi comparing four schizophrenia agents in phase II meta-trial
30. Characterization of tachykinin NK3 receptors in the rat isolated oesophagus
31. Information pack - Sanofi-Synthélabo - A brighter future together
32. Lehman Brothers: Pharmaceuticals Europe: Sanofi-Synthélabo
33. Sanofi-Synthelabo Financial Analysts Meeting
34. SR142801 behaves as a tachykinin NK-3 receptor agonist on a spinal nociceptive reflex in the rat
35. Spinal neurokinin3 receptors mediate thermal but not mechanical hyperalgesia via nitric oxide
36. Tachykinin NK(3)receptor involvement in anxiety
37. Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs
38. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea pig
39. Effect of tachykinin receptor antagonists in experimental neuropathic pain
40. Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice
41. Localization of Fos-like immunoreactivity induced by the NK3 tachykinin receptor agonist, senktide, in the guinea-pig brain
42. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat
43. Molecular characterisation, expression and localisation of human neurokinin-3 receptor
44. Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat
45. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test
46. EP-00673928: Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists
47. Products development pipeline: R&D Portfolio